Showing 5 results for Hyperuricemia
Oloomi Z, Moayeri H, Bahremand Sh, Vafaei P,
Volume 65, Issue 1 (3-2008)
Abstract
Background: Hyperuricemia is one of the oncologic emergency that occurs most often in patients with hematologic disorders particularly leukemia and high-grade lymphoma. This study was conducted in order to determine the prevalence of hyperuricemia with respect to prophylactic treatment (in particular allopurinol) in patients with lymphoproliferative disease in the pediatric hematologic ward of Imam Khomeini Hospital, Tehran.
Methods: In this retrospective cross-sectional study, 316 children (75 females, 241 males) under the age of 12 years participated. Among the subjects, 66 patients (20.9%) had lymphoma and 250 patients (79.1%) had leukemia.
Results: Of the 56 (17.7%) patients diagnosed with hyperuricemia, 13 with lymphoma (19.7%) and 43 (17.2%) with acute lymphoblastic leukemia, 52 patients showed hyperuricemia after induction of chemotherapy (p<0.001). Hyperuricemia was more prevalent in patients with more advanced disease (50.9% in stage IV, p<0.001). Hyperuricemia was more frequent in male patients (p<0.001). Among the 217 patients who had received prophylaxis (hydration, alkalization, allopurinol), 19 (8.7%) subjects had hyperuricemia compare to 37.3% in the group of patients who did not receive prophylactic treatment (p<0.001).
Conclusion: From the literature reviewed, a recombinant form of the urate oxidase enzyme (rasburicase) is a safe and effective alternative to allopurinol to rapidly control plasma uric acid concentrations in patients with hematologic malignancy at high risk for tumor lysis during induction of chemotherapy. In this respect, we recommend a prospective study to compare allopurinol and rasburicase in children with leukemia and lymphoma.
Oloomi Z, Moayeri H,
Volume 65, Issue 13 (3-2008)
Abstract
Background: Hyperuricemia is one of the oncologic emergency that occurs most often in patients with hematologic disorders particularly leukemia and high-grade lymphoma. This study was conducted in order to determine the prevalence of hyperuricemia with respect to prophylactic treatment (in particular allopurinol) in patients with lymphoproliferative disease in the pediatric hematologic ward of Imam Khomeini Hospital, Tehran.
Methods: In this retrospective cross-sectional study, 316 children (75 females, 241 males) under the age of 12 years participated. Among the subjects, 66 patients (20.9%) had lymphoma and 250 patients (79.1%) had leukemia.
Results: Of the 56 (17.7%) patients diagnosed with hyperuricemia, 13 with lymphoma (19.7%) and 43 (17.2%) with acute lymphoblastic leukemia, 52 patients showed hyperuricemia after induction of chemotherapy (p<0.001). Hyperuricemia was more prevalent in patients with more advanced disease (50.9% in stage IV, p<0.001). Hyperuricemia was more frequent in male patients (p<0.001). Among the 217 patients who had received prophylaxis (hydration, alkalization, allopurinol), 19 (8.7%) subjects had hyperuricemia compare to 37.3% in the group of patients who did not receive prophylactic treatment (p<0.001).
Conclusion: From the literature reviewed, a recombinant form of the urate oxidase enzyme (rasburicase) is a safe and effective alternative to allopurinol to rapidly control plasma uric acid concentrations in patients with hematologic malignancy at high risk for tumor lysis during induction of chemotherapy. In this respect, we recommend a prospective study to compare allopurinol and rasburicase in children with leukemia and lymphoma.
Ahmadi F, Naseri R, Lessan Pezeshki M,
Volume 66, Issue 7 (10-2008)
Abstract
Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Cyclosporine
is one of the main immunosuppressors used for renal transplant recipients, and
is given to prevent transplant rejection. Although the drug increases the
survival of patients and grafted organs, it has some side effects independent
of its effect on the immune system that are usually ignored. In this study, we
evaluate the effect of cyclosporine on serum Mg levels and metabolic side
effects in renal graft patients.
Methods: In this study, we followed 157 renal
transplant recipients (62 females and 95 males) who were being treated with cyclosporine at a
private clinic to prevent transplant rejection. The patients were first physically
examined and then blood samples were obtained in order to measure levels of
cyclosporine, Mg, creatinine, fasting blood sugar, lipids, calcium,
phosphorus, and uric acid levels. We then analyzed the data for correlations between
serum Mg
levels, cyclosporine and other metabolic complications.
Results: The mean levels of Mg and
cyclosporine were 196±0.31mg/dl and 371±192 μg/dl, respectively. Hypomagnesemia was detected in 16 patients (10.2%).There was
a significant negative correlation (p<0.05) between levels of Mg and cyclosporine levels (r=-0.53), serum
creatinine (r=-0.61), plasma LDL (r=-0.3), fasting blood sugar (r=-0.60) and uric
acid (r=-0.36), and no correlation (p>0.05) between levels of Mg and calcium (r=0.2), phosphorus (r=-0.01),
triglycerides (r=0.06) and HDL (r=-0.08). Mean levels of cyclosporine, creatinine, LDL, fasting
blood sugar and uric acid in patients with hypomagnesemia were significantly
different from those patients with normal serum Mg levels (p<0.05). There
was no significant difference between the two groups with regard to mean total
cholesterol, HDL, calcium and phosphorus (p>0.05).
Conclusion: According to the results of this and previous studies,
there is a significant correlation between cyclosporine levels and
hypomagnesemia as well as other biomedical complications secondary to
hypomagnesemia. Therefore, we recommend routine serum Mg determination and greater
attention to hypomagnesemic patients to prevent further complications.
Sattarzade Badkoobeh R, Nozari Y, Larti F, Safari S, Ahmadi F, Emami M,
Volume 68, Issue 10 (1-2011)
Abstract
Background: The role of reactive oxygen
species (ROS) in the pathogenesis
of different cardiac diseases has been documented. Recently, effect of
allopurinol in decreasing the production of ROS and
improving cardiovascular pathogenesis has come into scientific interest. Animal
studies have documented the benefit of allopurinol in improving left
ventricular dilatation, hypertrophy and fibrosis, and myocardial contractility
and in the prevention of systemic vasoconstriction. The aim of this study was
to evaluate the effect of allopurinol in improving diastolic dysfunction in ESRD
patients with hyperuricemia.
Methods: This was an interventional study on 28 patients
(19 males and 9 females)
with ESRD and hyperuricemia. At the end of a one-month
course of allopurinol therapy (100 mg daily),
echocardiographic indices of diastolic dysfunction were measured and compared
to the baseline indices.
Results: The mean level of uric acid was 7.5±0.96 mg/dl. The
mean EF before and after the study were %44.28±%9.8
and %44.64±%9.7, (no significant difference),
Respectively. The two indices of IVCT and
A reversal were shown to have significant
improvement after therapy (p=0.028 and 0.012,
respectively). The grading of diastolic dysfunction didn't improve
significantly after treatment with allopurinol.
Conclusion: Significant
improvement in some of studied indices, reproduced only in male subgroup of
patients that might be related to a better response of males to allopurinol,
however, a longer course of treatment may result in more favorable responses.
Better patient selection in terms of "EF"s
with normal distribution and repeating the study in non-dialysis hyperuricemic
patients may result in more accurate information.
Ghiasi M, Ehsani Ah, Dahande A, Abdoreza M,
Volume 70, Issue 1 (4-2012)
Abstract
Background: Psoriasis is a common, chronic disease of the skin, in which both genetic and environmental factors play a critical role. The most characteristic lesions consist of red, scaly plaques present particularly over extensor surfaces and scalp. Studies have reported association between psoriasis and many other diseases in both cutaneous and systemic forms of the disease. Several studies with different and sometimes controversial results have been done about the relationship of hyperuricemia and psoriasis. The aim of our study was to assess serum uric acid levels in patients with psoriasis.
Methods: We studied 126 patients with psoriasis in a case-series study in Razi Hospital during one year. After recording the age, sex, duration, type and severity of the disease and presence or absence of psoriatic arthritis in the patients, they were referred to the laboratory for the determination of serum uric acid concentrations.
Results: The mean (±SD) serum uric acid level was 5.4±1.5 mg/dL (ranging from 1.9- 9.5 mg/dL). Although the mean serum uric acid levels were in the normal range but the values were significantly higher in patients with more severe forms of psoriasis (P<0.001), its longer duration (P<0.001) and psoriatic arthritis (P=0.003). Moreover, serum uric acid levels were significantly higher in patients with non-plaque-type than plaque-type psoriasis (P=0.01).
Conclusion: This study revealed that serum uric acid levels exacerbate by increases in the severity and duration of psoriasis, in psoriatic arthritis, and in patients with non-plaque-type psoriasis.
